Home › Ulcerative Colitis › NCT05953402

A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring

ZEPOSIA® (Ozanimod) Ulcerative Colitis Pregnancy Registry: a Prospective, Observational Study on the Safety of Ozanimod Exposure in Pregnant Women With Ulcerative Colitis and Their Offspring

Who can join

All ages · Women

Inclusion Criteria:

* Currently or recently pregnant
* Diagnosis of UC
* Resident of country where ozanimod is prescribed for the treatment of UC

Exclusion Criteria:

* Exposure to other S1P therapies at any time during pregnancy

Other protocol-defined eligibility criteria apply.

About the study

The purpose of this study is to evaluate association between ozanimod exposure during pregnancy and subsequent maternal, fetal, and infant outcomes.

Sponsor: Bristol-Myers Squibb · Participants: 1,182 · Started: Apr 21, 2026

Contact the study team

• BMS Study Connect Contact Center www.BMSStudyConnect.com · Phone: 855-907-3286

Official record on ClinicalTrials.gov — NCT05953402

Locations in the U.S.

Conditions

• Ulcerative Colitis
• Inflammatory Bowel Disease

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.